11-year-old Violet finds a feeling of freedom when figure skating. She loves the sport and has had Olympic aspirations since she began skating at three years old. But in 2020, Violet was diagnosed with myopia, potentially presenting a challenge for her rigorous training and competition. Both of Violet’s parents have myopia, which made her six times more likely to develop the condition.[1]
To treat Violet’s myopia, while providing the visual acuity and convenience, Dr. Pamela Wu of Spectrum Optometry prescribed MiSight® 1 day for myopia control.*‡ MiSight® 1 day contact lenses are the first, and only, FDA-approved* soft contact lenses proven to slow myopia progression in children aged 8-12 at the initiation of treatment.[2]† Since her first appointment with Dr. Wu two years ago, Violet’s myopia has not progressed. MiSight®1 day reduces the rate of myopia progression in age-appropriate children by 59% on average over a three-year period.2†
Watch Violet’s story for more about her experience with myopia and myopia control. To learn more about the MiSight® 1 contact lenses, and to become MiSight® certified, visit our ECP ViewpointsSM Online Success Center, a one-stop digital education platform for ECPs.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3-year period
‡ Soft contact lens designed for myopia control in the U.S.
[1] Mutti DO, Mitchell GL, Moeschberger ML, Jones LA, Zadnik K. Parental myopia, near work, school achievement, and children's refractive error. Invest Ophthalmol Vis Sci. 2002;43(12):3633-3640. doi:10.1001/jamaophthalmol.2020.0412
[2] Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019;96(8):556-567
